Latest Biologic - just in case:
Dewi here:
Not sure if you've seen this, so just in case:
On January 21, 2022 the U.S. Food and Drug Administration (FDA) approved SKYRIZI® (risankizumab-rzaa), an interleukin-23 inhibitor, for the treatment of active psoriatic arthritis (PsA) in adults.
Awesome, thanks
! Jill, Team Member
